Further validation of LABORAS™ using various dopaminergic manipulations in mice including MPTP-induced nigro-striatal degeneration

Arai, 1990, Evaluation of a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated C57 black mouse model of parkinsonism, Brain Res, 515, 57, 10.1016/0006-8993(90)90576-W Berardelli, 2001, Pathophysiology of bradykinesia in Parkinson's disease, Brain, 124, 2131, 10.1093/brain/124.11.2131 Bezard, 1998, Compensatory mechanisms in experimental and human parkinsonism: towards a dynamic approach, Prog Neurobiol, 55, 93, 10.1016/S0301-0082(98)00006-9 Chia, 1996, Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 5,7-dihydroxytryptamine on the locomotor activity and striatal amines in C57BL/6 mice, Neurosci Lett, 218, 67, 10.1016/0304-3940(96)13091-3 Di Chiara, 1976, Evidence of dopamine receptors mediating sedation in the mouse brain, Nature, 264, 564, 10.1038/264564a0 Franklin, 1997 Fredriksson, 1994, MPTP-induced behavioural and biochemical deficits: a parametric analysis, J Neural Transm, 7, 123, 10.1007/BF02260967 Fredriksson, 1997, MPTP-induced deficits in motor activity: neuroprotective effects of the spintrapping agent, α-phenyl-tert-butyl-nitrone (PBN), J Neural Transm, 104, 579, 10.1007/BF01291877 Gronan, 1975, Time and dose influences on the behavioural effects of l-DOPA and 5-hydroxytryptophan after inhibition of extracerebral decarboxylase, Pharmacol Biochem Behav, 3, 161, 10.1016/0091-3057(75)90142-2 Heikkila, 1984, Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice, Science, 224, 1451, 10.1126/science.6610213 Irifune, 1995, Effects of GBR12909 on locomotor activity and dopamine turnover in mice: comparison with apomorphine, Eur J Pharmacol, 272, 79, 10.1016/0014-2999(94)00620-M Johnson, 1976, Stimulant properties of bromocriptine on central dopamine receptors in comparison to apomorphine, (+)-amphetamine and l-DOPA, Br J Pharmacol, 56, 59, 10.1111/j.1476-5381.1976.tb06959.x Jonkers, 2001, Benserazide decreases central AADC activity, extracellular dopamine levels and levodopa decarboxylation in striatum of the rat, J Neural Transm, 108, 559, 10.1007/s007020170056 Matsumoto, 1990, Methamphetamine- and apomorphine-induced changes in spontaneous motor activity using a new system to detect and analyse motor activity in mice, J Pharmacol Meth, 24, 111, 10.1016/0160-5402(90)90022-D Nishi, 1991, Destruction of norepinephrine terminals in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice reduces locomotor activity induced by l-DOPA, Neurosci Lett, 123, 244, 10.1016/0304-3940(91)90941-L Ogawa, 1987, MPTP-induced parkinsonian model in mice: biochemistry, pharmacology and behaviour, Eur Neurol, 26, 16, 10.1159/000116351 O’Neill, 1999, Comparison of dopamine receptor antagonists on hyperlocomotion induced by cocaine, amphetamine, MK-801 and the dopamine D1 agonist C-APB in mice, Psychopharmacology, 145, 237, 10.1007/s002130051055 Quinn, 2001, LABORAS™ system validation: using orexin-A induced grooming. Monitoring molecules in neuroscience, 31 Quinn, 2003, LABORAS™: initial pharmacological validation of a system allowing continuous monitoring of laboratory rodent behaviour, J Neurosci Meth, 130, 83, 10.1016/S0165-0270(03)00227-9 Quinn, 2005, A novel behavioural registration system LABORAS™ and the social interaction paradigm detect long-term functional deficits following middle cerebral artery occlusion in the rat, Brain Res, 1031, 118, 10.1016/j.brainres.2004.10.036 Rascol, 2002, Treatment interventions for Parkinsons disease: an evidence based assessment, Lancet, 359, 1589, 10.1016/S0140-6736(02)08520-3 Ricaurte, 1987, Aging and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced degeneration of dopaminergic neurons in the substantia nigra, Brain Res, 403, 43, 10.1016/0006-8993(87)90120-X Rousselet, 2003, Behavioural changes are not directly related to striatal monoamine levels, number of nigral neurons, or dose of Parkinsonian toxin MPTP in mice, Neurobiol Dis, 14, 218, 10.1016/S0969-9961(03)00108-6 Rozas, 1998, The overall rod performance test in the MPTP-treated mouse model of parkinsonism, J Neurosci Meth, 83, 165, 10.1016/S0165-0270(98)00078-8 Schlingmann, 1998, A balance device for the analysis of behavioural patterns of the mouse, Anim Welfare, 7, 177, 10.1017/S0962728600020480 Schroeder, 1997, Amphetamine induces hypermotility in MPTP lesioned mice, Pharmacol Biochem Behav, 56, 281, 10.1016/S0091-3057(96)00291-2 Sedelis, 2000, MPTP susceptibility in the mouse: behavioural, neurochemical, and histological analysis of gender and strain differences, Behav Genet, 30, 171, 10.1023/A:1001958023096 Simon, 2000, Predicting how equipotent doses of chlorpromazine, haloperidol, sulpiride, raclopride and clozapine reduce locomotor activity in mice, Eur Neuropsychopharmacol, 10, 159, 10.1016/S0924-977X(00)00070-5 Sonsalla, 1986, The influence of dose and dosing interval on MPTP-induced dopaminergic neurotoxicity in mice, Eur J Pharmacol, 129, 339, 10.1016/0014-2999(86)90444-9 Starr, 1986, Differential effects of dopamine D1 and D2 agonists and antagonists on velocity of movement, rearing and grooming in the mouse, Neuropharmacology, 25, 455, 10.1016/0028-3908(86)90168-1 Stromberg, 1975, Differences between (+)- and (−)-amphetamine in effects on locomotor activity and l-DOPA potentiating action in mice, Naunyn-Schmiedeberg's Arch Pharmacol, 287, 171, 10.1007/BF00510448 Sundstrom, 1987, Studies on the effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in C57BL/6 mice. Comparison with three other strains of mice, Brain Res, 405, 26, 10.1016/0006-8993(87)90986-3 Thomas, 1978, On the mechanism of amphetamine-induced behavioural changes in mouse: III. Effects of apomorphine and fla 63, Arzneim-Forsch/Drug Res, 28, 993 Ushijima, 1995, Development of tolerance and reverse tolerance to haloperidol and SCH23390-induced cataleptic effects during withdrawal periods after long term treatment, Pharmacol Biochem Behav, 50, 259, 10.1016/0091-3057(94)00309-7 Van de Weerd, 2001, Validation of a new system for automatic registration of behaviour in mice and rats, Behav Process, 53, 11, 10.1016/S0376-6357(00)00135-2 Vasse, 1988, Increased grooming behaviour in induced by apomorphine in mice treated with discriminant benzamide derivatives, Eur J Pharmacol, 156, 1, 10.1016/0014-2999(88)90141-0 Vetulani, 1982, Analysis of the difference in the behavioural effects of apomorphine in C57BL/6 and DBA/2 mice, Pharmacol Biochem Behav, 7, 967, 10.1016/0091-3057(82)90481-6 Vetulani, 2001, Opposite effect of simple tetrahydroisoquinolines on amphetamine- and morphine-stimulated locomotor activity in mice, J Neural Transm, 108, 513, 10.1007/s007020170053 Willis, 1987, Histochemical, biochemical and behavioural consequences of MPTP treatment in C-57 black mice, Brain Res, 402, 269, 10.1016/0006-8993(87)90033-3